Drugmakers Fight FTC Bid For Privileged Antitrust Risk Docs
Law360, New York (August 11, 2015, 8:36 PM EDT) -- AbbVie Products LLC and other drugmakers being sued by the Federal Trade Commission and private plaintiffs over patent pay-for-delay settlements for testosterone drug AndroGel have told a Georgia federal court to reject a bid that would force them to turn over details of their settlement negotiations.
The companies filed an opposition to a July motion by the FTC and others that had asked the court to force AbbVie and fellow defendants Actavis Inc., Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. to produce the documents and allow witnesses to be questioned about settlement discussions conducted by the companies’ lawyers in 2006....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.